In breast carcinomas, the two most frequently mutated genes, TP53 and PIK3CA, are present in 2937/5906 (49.7%) and 4479/16715 (26.8%) of solid tumors, respectively (COSMIC database; [6]), garnering interest as potential avenues for targeted therapy. The gene discussed is PIK3CA; the disease is breast carcinoma.